Compare HAWK & AAPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HAWK | AAPG |
|---|---|---|
| Founded | 2015 | 2009 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.4B |
| IPO Year | 2026 | 2024 |
| Metric | HAWK | AAPG |
|---|---|---|
| Price | $12.33 | $15.13 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 11 |
| Target Price | $29.10 | ★ $43.27 |
| AVG Volume (30 Days) | ★ 1.3M | 4.9K |
| Earning Date | 11-12-2026 | 08-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $84.65 | $18.59 |
| Revenue Next Year | $25.27 | $120.05 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.41 | $14.46 |
| 52 Week High | $25.71 | $35.07 |
| Indicator | HAWK | AAPG |
|---|---|---|
| Relative Strength Index (RSI) | 30.59 | 49.14 |
| Support Level | N/A | $14.50 |
| Resistance Level | $17.42 | $16.34 |
| Average True Range (ATR) | 0.64 | 0.51 |
| MACD | 0.02 | 0.12 |
| Stochastic Oscillator | 30.89 | 47.02 |
Hawkeye 360 Inc operates in the signals intelligence (SIGINT) and defense technology sector. It provides end-to-end signals intelligence solutions integrated into national security systems for the United States and allied customers. Its offerings include radio frequency data and related insights to support defense operations. The company is involved across the value chain, including satellite design and manufacturing, data collection, and data processing and analysis. It generates revenue prominently from fixed price contract arrangements for RF signal mapping products that are used to analyze and track radio waves.
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies and currently has seven drug candidates in pipeline under research. The company's geographical segments include the United States and Mainland China.